Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026
Oncology, Medical February 17th 2026
Conexiant
The Aptima HPV assay uses messenger RNA detection to identify infections most likely to lead to cervical cancer.
Obstetrics & Gynecology February 11th 2026
Annals of Internal Medicine
Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.
Family Medicine/General Practice February 6th 2026
Oncology News Central (ONC)
“As an oncologist, when patients lost their hair, my response was, ‘Don’t worry. It will grow back.’ And it will grow back. But it really sucks as you’re waiting.” – Dr. Sue Hwang
Oncology, Medical February 2nd 2026
The brothers falsely inflated OP-1250’s overall response rate from 9% to 17% and bumped up the expected phase II response rate from 18% to 36%.
Oncology Pharmacy February 2nd 2026
Medical Xpress
The findings provide significant conceptual advances into cancer neuroscience and establish therapeutic avenues that are distinct from present amyloid-lowering strategies, aiming at degrading the existing amyloid plaques.
Geriatrics February 2nd 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS